Folfox6

Phase 1Small molecule

HHenry Ford Health System

Folfox6 is one of 3 small molecule programs targeting SAR445877. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SAR445877Recruiting

SAR445877Phase 1

Recruiting

Competition

Competitive Landscape

2 competitors in SAR445877

#DrugCompanyPhaseTrials

Avastin

Roche

Phase 1

1 2

SAR445877

Sanofi

Phase 1

1 3

Folfox6

HHenry Ford Health System

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2032

Phase 1Recruiting

SAR445877

NCT07500298

Clinical

Trials by Indication[1]

Pancreatic Cancer1 trial

Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer

Completed·HHenry Ford Health System·Phase 2·NCT02243358·24 enrolled

Completed·FFudan University·Phase 2·NCT01605305·60 enrolled

Rectal Cancer1 trial

5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT01749956·39 enrolled

3 more indications

Gastrointestinal1 trial

Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 1·NCT01420874·15 enrolled

Neoadjuvant Treatment1 trial

Complete Neoadjuvant Treatment for REctal Cancer (CONTRE)

Completed·WWilliam Sikov MD·Phase 2·NCT01363843·39 enrolled

SAR4458771 trial

Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT07500298·41 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Folfox6. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Folfox6 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Folfox6. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Henry Ford Health System company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: HHenry Ford Health System

Folfox6

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2032

Trials by Indication[1]

Pancreatic Cancer1 trial

Liver Metastases1 trial

Chemoradiation1 trial

Esophageal Cancer1 trial

Rectal Cancer1 trial

Gastrointestinal1 trial

Neoadjuvant Treatment1 trial

SAR4458771 trial

References

Drug Info

Quick Facts

Related News